24
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Fluvoxamine Attenuated Endoplasmic Reticulum Stress-Induced Leptin Resistance

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Increasing evidence indicates that endoplasmic reticulum stress (ER stress) is involved in the development of metabolic syndrome. However, pharmacological treatments targeting ER stress are not well understood. In the present study, we found that fluvoxamine, a selective serotonin reuptake inhibitor used for depression, can attenuate ER stress-induced “leptin resistance,” i.e., insensitivity to the anti-obesity hormone leptin. Treatment with tunicamycin, an ER stress-inducing reagent, caused cell death which was significantly inhibited by fluvoxamine. Leptin activates JAK2–STAT3 signaling. ER stress caused an impairment of leptin-induced STAT3 phosphorylation which was reversed by fluvoxamine. Fluvoxamine would be a novel leptin-sensitizing drug, which targets ER stress.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: not found

          Positional cloning of the mouse obese gene and its human homologue.

          The mechanisms that balance food intake and energy expenditure determine who will be obese and who will be lean. One of the molecules that regulates energy balance in the mouse is the obese (ob) gene. Mutation of ob results in profound obesity and type II diabetes as part of a syndrome that resembles morbid obesity in humans. The ob gene product may function as part of a signalling pathway from adipose tissue that acts to regulate the size of the body fat depot.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Association between obesity and psychiatric disorders in the US adult population.

            Epidemiologic data suggest an association between obesity and depression, but findings vary across studies and suggest a stronger relationship in women than men. To evaluate the relationship between obesity and a range of mood, anxiety, and substance use disorders in the US general population. Cross-sectional epidemiologic survey. Nationally representative sample of US adults. A total of 9125 respondents who provided complete data on psychiatric disorder, height, and weight. Response rate was 70.9%. Participants completed an in-person interview, including assessment of a range of mental disorders (assessed using the World Health Organization Composite International Diagnostic Interview) and height and weight (by self-report). Obesity (defined as body mass index [calculated as weight in kilograms divided by the square of height in meters] of > or =30) was associated with significant increases in lifetime diagnosis of major depression (odds ratio [OR], 1.21; 95% confidence interval [CI], 1.09-1.35), bipolar disorder (OR, 1.47; 95% CI, 1.12-1.93), and panic disorder or agoraphobia (OR, 1.27; 95% CI, 1.01-1.60). Obesity was associated with significantly lower lifetime risk of substance use disorder (OR, 0.78; 95% CI, 0.65-0.93). Subgroup analyses found no difference in these associations between men and women, but the association between obesity and mood disorder was strongest in non-Hispanic whites (OR, 1.38; 95% CI, 1.20-1.59) and college graduates (OR, 1.44; 95% CI, 1.14-1.81). Obesity is associated with an approximately 25% increase in odds of mood and anxiety disorders and an approximately 25% decrease in odds of substance use disorders. Variation across demographic groups suggests that social or cultural factors may moderate or mediate the association between obesity and mood disorder.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Endoplasmic reticulum stress plays a central role in development of leptin resistance.

              Leptin has not evolved as a therapeutic modality for the treatment of obesity due to the prevalence of leptin resistance in a majority of the obese population. Nevertheless, the molecular mechanisms of leptin resistance remain poorly understood. Here, we show that increased endoplasmic reticulum (ER) stress and activation of the unfolded protein response (UPR) in the hypothalamus of obese mice inhibits leptin receptor signaling. The genetic imposition of reduced ER capacity in mice results in severe leptin resistance and leads to a significant augmentation of obesity on a high-fat diet. Moreover, we show that chemical chaperones, 4-phenyl butyric acid (PBA), and tauroursodeoxycholic acid (TUDCA), which have the ability to decrease ER stress, act as leptin-sensitizing agents. Taken together, our results may provide the basis for a novel treatment of obesity.
                Bookmark

                Author and article information

                Journal
                Front Endocrinol (Lausanne)
                Front Endocrinol (Lausanne)
                Front. Endocrin.
                Frontiers in Endocrinology
                Frontiers Research Foundation
                1664-2392
                30 January 2012
                2012
                : 3
                : 12
                Affiliations
                [1] 1simpleDepartment of Pharmacotherapy, Graduate School of Biomedical Sciences, Hiroshima University Minami-ku, Hiroshima, Japan
                Author notes

                Edited by: Arthur Donny Strosberg, The Scripps Research Organization, USA

                Reviewed by: Donghai Wu, Guangzhou Institute of Biomedicine and Health, China; Timo Dirk Mueller, University of Cincinnati Metabolic Diseases Institute, USA

                *Correspondence: Toru Hosoi and Koichiro Ozawa, Department of Pharmacotherapy, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan. e-mail: toruh@ 123456hiroshima-u.ac.jp ; ozawak@ 123456hiroshima-u.ac.jp

                This article was submitted to Frontiers in Cellular Endocrinology, a specialty of Frontiers in Endocrinology.

                Article
                10.3389/fendo.2012.00012
                3355886
                22649406
                9ce3bb1c-ef3a-484a-979b-78157e7d2c25
                Copyright © 2012 Hosoi, Miyahara, Kayano, Yokoyama and Ozawa.

                This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.

                History
                : 16 April 2011
                : 12 January 2012
                Page count
                Figures: 5, Tables: 0, Equations: 0, References: 31, Pages: 5, Words: 3482
                Categories
                Endocrinology
                Original Research

                Endocrinology & Diabetes
                obesity,stat3,depression,leptin,endoplasmic reticulum stress,fluvoxamine
                Endocrinology & Diabetes
                obesity, stat3, depression, leptin, endoplasmic reticulum stress, fluvoxamine

                Comments

                Comment on this article